OSU College of Pharmacy Videos Promote ASBM Biosimilars CE Course

On May 31st, the Ohio State University College of Pharmacy released a series of promotional videos for its 7-hour continuing education (CE) program on biosimilars. The videos consist of an overview of the educational program featuring all the presenters, as well as a biographical sketch of each presenter. The program was developed in partnership with ASBM and […]

ASBM to Present U.S. Physician Survey Data at DIA Global Annual Meeting

On June 20th, ASBM Chairman Ralph McKibbin, MD will present a poster entitled “Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” at the 2022 DIA Global Annual Meeting in Chicago, IL. The poster is based on the findings of ASBM’s September 2021 survey of 401 U.S. physicians. While topline findings have been shared privately in meetings […]

ASBM and GCCA Host Biosimilar Training Program

On May 10-11, ASBM sponsored a live, two-day Biosimilars Training Program presented by the Global Colon Cancer Association, in partnership with the World Patient Alliance. Those who were unable to attend the live event may now watch sessions on-demand at LearnBiosimilars.org. The event is open to patients from any disease state. This two-day interactive program is designed to […]

ASBM Submits Comments on Health Canada’s Biosimilar Handbook for HCPs

On April 29th, ASBM submitted comments to Health Canada as part of a stakeholder consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. One key area of focus for ASBM’s comments was mixed messaging surrounding biosimilar equivalence and switching, including language which implies, inaccurately, that Canada’s policies were consistent with those of regulators in […]

ASBM Presents at WHO’s 74th INN Consultation

On April 5th, ASBM participated in the World Health Organization’s 74th Consultation on International Non-proprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. This was the eighteenth INN Consultation in which ASBM has participated. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board Chair Philip Schneider, MS, FASHP. The proceedings at the […]

ASBM Letter Opposes MN Bill That Could Raise Costs for Patients

On April 7th, ASBM sent a letter to Minnesota lawmakers opposing a bill which could potentially increase costs for patients who receive biologic medicines. The bill, HF 1516, was introduced last session but not ultimately adopted. ASBM led a coalition of patient organizations that raised concerns with the bill last spring. From the letter: It […]

Canadian PMPRB Responds to Patient Concerns

On April 14, 2022, the Honourable Jean-Yves Duclos, Canadian Minister of Health, issued a statement announcing the Government’s intention related to the coming-into-force of the Amendments to the Patented Medicine Prices Review Board (PMPRB) Regulations. The Minister’s statement advised that Health Canada will proceed with changing the new basket of comparator countries and will not proceed with […]

ASBM Video Shares US Physician Perspectives on Non-Medical Switching

ASBM has released our latest video, “Non-Medical Switching”, featuring ASBM Chairman Ralph McKibbin, MD. In the video, Dr. McKibbin shares new data from ASBM’s recent survey of 401 U.S. prescribers of biologics, as well as his own observations on the controversial practice. Among the survey findings: 69% of US physicians surveyed consider it “very important or critical” […]

ASBM Leads Sessions at Festival of Biologics USA 2022

From March 9-11, ASBM participated in the Festival of Biologics USA 2022, held in San Diego, California. Several ASBM representatives presented on a variety of topics, and participated in several discussion panels at the three-day conference. On March 9th, ASBM Advisory Board Chair Philip Schneider gave a plenary presentation on the current biosimilars landscape, highlighting factors which […]

More News
OSU College of Pharmacy Videos Promote ASBM Biosimilars CE Course

OSU College of Pharmacy Videos Promote ASBM Biosimilars CE Course

On May 31st, the Ohio State University College of Pharmacy released a series of promotional videos for its 7-hour continuing education (CE) program on biosimilars. The videos consist of an overview of the educational program featuring all the presenters, as well as a biographical sketch of each presenter. The program was developed in partnership with ASBM and […]

FDA/University of Maryland Biosimilars Workshop Online

FDA/University of Maryland Biosimilars Workshop Online

On April 13th, the U.S. Food and Drug Administration (FDA) and The University of Maryland Center of Excellence in Regulatory Science (M-CERSI) held an educational webinar entitled “Biosimilars: A Decade of Experience and Future Directions-Strategies for Improving Biosimilar Adoption and the Potential Role of Clinical Pharmacology”. In the workshop, leading academic clinicians with specialties in oncology, […]

ASBM to Present U.S. Physician Survey Data at DIA Global Annual Meeting

ASBM to Present U.S. Physician Survey Data at DIA Global Annual Meeting

On June 20th, ASBM Chairman Ralph McKibbin, MD will present a poster entitled “Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” at the 2022 DIA Global Annual Meeting in Chicago, IL. The poster is based on the findings of ASBM’s September 2021 survey of 401 U.S. physicians. While topline findings have been shared privately in meetings […]

ASBM Submits Comments on Health Canada’s Biosimilar Handbook for HCPs

ASBM Submits Comments on Health Canada’s Biosimilar Handbook for HCPs

On April 29th, ASBM submitted comments to Health Canada as part of a stakeholder consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. One key area of focus for ASBM’s comments was mixed messaging surrounding biosimilar equivalence and switching, including language which implies, inaccurately, that Canada’s policies were consistent with those of regulators in […]

Canadian PMPRB Responds to Patient Concerns

Canadian PMPRB Responds to Patient Concerns

On April 14, 2022, the Honourable Jean-Yves Duclos, Canadian Minister of Health, issued a statement announcing the Government’s intention related to the coming-into-force of the Amendments to the Patented Medicine Prices Review Board (PMPRB) Regulations. The Minister’s statement advised that Health Canada will proceed with changing the new basket of comparator countries and will not proceed with […]

Biosimilars 101

Biologic medicines are used to treat millions of patients with serious illnesses like cancer, arthritis, and psoriasis. The patents for many biologic therapies are expiring over the coming years, and biosimilars will be entering the marketplace. Regulatory authorities around the world have put policies in place to ensure that biosimilars have been appropriately tested, and are safe and effective for patients.

Member Partners

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups and individuals—from patients to physicians, biotechnology companies that develop innovative and biosimilar medicines and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

logo logo logo